EagleClaw Capital Managment LLC Sells 75 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

EagleClaw Capital Managment LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.2% in the 3rd quarter, HoldingsChannel reports. The fund owned 6,284 shares of the medical research company’s stock after selling 75 shares during the period. EagleClaw Capital Managment LLC’s holdings in Thermo Fisher Scientific were worth $3,887,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Ossiam increased its stake in shares of Thermo Fisher Scientific by 13.1% in the first quarter. Ossiam now owns 10,422 shares of the medical research company’s stock valued at $6,057,000 after buying an additional 1,205 shares during the period. LGT Group Foundation increased its position in Thermo Fisher Scientific by 8.9% during the 1st quarter. LGT Group Foundation now owns 3,179 shares of the medical research company’s stock valued at $1,848,000 after purchasing an additional 260 shares during the period. Delap Wealth Advisory LLC bought a new position in Thermo Fisher Scientific during the 1st quarter worth approximately $348,000. CreativeOne Wealth LLC boosted its stake in shares of Thermo Fisher Scientific by 20.9% in the 1st quarter. CreativeOne Wealth LLC now owns 5,478 shares of the medical research company’s stock valued at $3,184,000 after purchasing an additional 947 shares during the last quarter. Finally, Wellington Wealth Strategies LLC. bought a new position in Thermo Fisher Scientific during the first quarter worth $1,545,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded up $7.83 during trading on Wednesday, reaching $509.12. The company’s stock had a trading volume of 3,658,663 shares, compared to its average volume of 1,491,361. The firm has a market cap of $194.74 billion, a price-to-earnings ratio of 31.92, a price-to-earnings-growth ratio of 3.39 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 12 month low of $465.90 and a 12 month high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The firm has a 50 day moving average of $581.75 and a 200-day moving average of $581.46.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. During the same quarter in the previous year, the firm posted $5.69 earnings per share. The company’s revenue for the quarter was up .2% on a year-over-year basis. Research analysts expect that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.31%. Thermo Fisher Scientific’s payout ratio is presently 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of recent analyst reports. TD Cowen increased their price target on Thermo Fisher Scientific from $656.00 to $686.00 in a report on Tuesday, October 22nd. Sanford C. Bernstein dropped their price target on Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating on the stock in a research note on Thursday, October 24th. Bernstein Bank raised their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 22nd. Royal Bank of Canada cut their target price on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Finally, UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $649.33.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. The trade was a 1.77 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 9,000 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $552.86, for a total value of $4,975,740.00. Following the completion of the transaction, the chief executive officer now owns 14,608 shares of the company’s stock, valued at approximately $8,076,178.88. This represents a 38.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,150 shares of company stock valued at $20,651,865 in the last 90 days. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.